CorMedix (NASDAQ:CRMD) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS

CorMedix (NASDAQ:CRMD) announced its quarterly earnings data on Thursday. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.01, FiscalAI reports. CorMedix had a net margin of 45.25% and a return on equity of 45.57%. The business had revenue of $101.93 million during the quarter, compared to the consensus estimate of $96.04 million.

Here are the key takeaways from CorMedix’s conference call:

• Second-quarter revenue rose to $101.9 million, including $66.1 million from DefenCath and $35.8 million from the acquired Melinta portfolio; adjusted EBITDA increased to $58.7 million.
• CorMedix signed a multi-year DefenCath supply agreement with its fifth major U.S. dialysis provider. The LDO will begin a pilot involving several hundred clinics in the third quarter, with potential expansion in 2027.
• The company reaffirmed 2026 revenue guidance of $325 million to $345 million and raised adjusted EBITDA guidance to $125 million to $140 million, while noting that post-TDAPA ordering patterns remain an uncertainty.
• CorMedix expects Mundipharma to submit an sNDA for REZZAYO as prophylaxis against invasive fungal disease in the third quarter, potentially leading to FDA action in the first half of 2027 following positive Phase III results.
• DefenCath volumes have stabilized among larger dialysis providers but experienced some attrition among smaller accounts after TDAPA expiration; meaningful volume growth may depend on the new LDO pilot and Medicare Advantage contracting, which is not included in 2026 guidance.

CorMedix Trading Up 14.6%

CRMD opened at $8.14 on Friday. The company has a current ratio of 2.97, a quick ratio of 2.74 and a debt-to-equity ratio of 0.33. The firm has a market cap of $638.58 million, a price-to-earnings ratio of 3.82 and a beta of 1.50. CorMedix has a 12 month low of $6.13 and a 12 month high of $14.96. The stock has a fifty day moving average price of $8.16 and a 200-day moving average price of $7.65.

Analyst Ratings Changes

CRMD has been the topic of a number of research analyst reports. D. Boral Capital restated a “buy” rating and issued a $14.00 target price on shares of CorMedix in a research note on Monday, April 27th. Leerink Partners boosted their price target on CorMedix from $13.00 to $14.00 and gave the company an “outperform” rating in a report on Tuesday, April 28th. Royal Bank Of Canada dropped their price objective on CorMedix from $14.00 to $13.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 7th. Citizens Jmp restated a “market outperform” rating and set a $19.00 price objective on shares of CorMedix in a report on Tuesday, April 28th. Finally, Needham & Company LLC lifted their target price on CorMedix from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, April 27th. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $14.86.

Trending Headlines about CorMedix

Here are the key news stories impacting CorMedix this week:

• Positive Sentiment: Q2 results exceeded expectations: CorMedix reported earnings of $0.29 per share versus analyst estimates ranging from $0.26 to $0.28. Revenue increased to $101.9 million, ahead of the approximately $96.0 million consensus estimate. Net income was $26.0 million, while adjusted EBITDA reached $58.7 million. CorMedix Second Quarter 2026 Financial Results
• Positive Sentiment: Profitability outlook improved: Management maintained its fiscal 2026 revenue guidance of $325 million to $345 million while raising adjusted EBITDA guidance, signaling stronger operating leverage and profitability prospects. CorMedix Financial Results and Business Update
• Positive Sentiment: Potential pipeline catalyst: The CEO expects to submit a supplemental filing by the third quarter for a fungal-disease treatment application. Progress on an expanded indication could increase the commercial opportunity for CorMedix’s products. CorMedix Supplemental Filing Update
• Neutral Sentiment: Analyst sentiment remains favorable: Brokerages currently assign CorMedix an average “Moderate Buy” recommendation. However, the fiscal 2026 revenue midpoint of $335 million is broadly in line with the $334.7 million analyst consensus, making the guidance more reassuring than incremental. CorMedix Moderate Buy Recommendation

Institutional Trading of CorMedix

Several hedge funds have recently modified their holdings of CRMD. State of Tennessee Department of Treasury purchased a new position in shares of CorMedix in the 4th quarter worth approximately $223,000. Empowered Funds LLC acquired a new stake in CorMedix in the fourth quarter valued at approximately $1,534,000. VARCOV Co. purchased a new position in CorMedix in the fourth quarter worth $1,987,000. Inspire Investing LLC acquired a new position in shares of CorMedix during the fourth quarter worth $1,247,000. Finally, Schonfeld Strategic Advisors LLC increased its position in shares of CorMedix by 105.4% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 43,431 shares of the company’s stock worth $505,000 after purchasing an additional 22,283 shares in the last quarter. 34.18% of the stock is owned by hedge funds and other institutional investors.

CorMedix Company Profile

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.